Immunotherapy plus hormone therapy for breast cancer that did not shrink after chemotherapy
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new immunotherapy drug (QL1706) combined with hormone therapy for breast cancer that is hormone receptor positive and HER2 negative, but did not respond well to initial chemotherapy. The goal is to see if this combination can shrink tumors before surgery and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have been diagnosed with early or locally advanced breast cancer that is hormone receptor positive and HER2 negative.
- You have received two cycles of neoadjuvant chemotherapy (TAC regimen) and your tumor did not shrink by 40% or more on MRI.
- You have not had any prior cancer treatment except those two chemotherapy cycles, and no prior immunotherapy.
- Your overall health allows you to be up and about (ECOG performance status 0 or 1) and you have a life expectancy of at least 12 weeks.
- Your heart and major organs (like liver, kidneys, and blood cells) are functioning normally, and you are willing to provide blood and tumor samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy given before surgery for a certain type of breast cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
This study tests a combination of an immunotherapy drug (toripalimab) and a targeted type of radiation called SBRT for breast cancer that didn't shrink with standard chemo. It aims to see if this combination can help your body fight the cancer better.
This trial tests whether the drug QL1706, given before surgery, can help treat hormone receptor positive and HER2-negative breast cancer. It is for people who have not yet had cancer spread to other parts of the body.
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
This trial tests a new drug called QL706 combined with chemotherapy, with or without another drug called bevacizumab, for people with cervical cancer that has returned or spread and no longer responds to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery for cervical cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes, and it is given as a neoadjuvant (before-surgery) approach.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.